Ivan Kairatov is a preeminent biopharma and health policy expert with a distinguished career spanning drug development, clinical research, and navigating the complexities of the American insurance landscape. With his deep technical background in innovation and a keen understanding of the administrative hurdles that often stall patient care, he has become a leading voice for systemic reform in the healthcare industry. Today, we explore the intricate web of prior authorizations, the gap between industry promises and patient reality, and the profound human cost of medical denials.
This conversation delves into the transparency of voluntary industry pledges, the clinical hazards of recurring reviews for chronic conditions, and the devastating financial and psychological burdens placed on families. We also examine the technicalities of the external appeals process, the shift toward bundled authorizations, and strategies for maintaining continuity of care during insurance transitions.
Industry leaders recently pledged to simplify prior authorizations by reducing the scope of claims and speeding up turnaround times. How do you assess the transparency of these voluntary rollouts so far, and what specific metrics should patients look for to determine if their insurer is actually reducing administrative barriers?
The current state of transparency is deeply concerning because many of these voluntary pledges lack the “teeth” of public accountability. When we contacted over a dozen major insurers who signed the June pledge, half of them failed to provide any specifics regarding which services were actually released from preapproval requirements. Organizations like AHIP and the Blue Cross Blue Shield Association have remained vague, often deferring to future updates rather than providing hard data on codes or medications. Patients should look for concrete, public lists of exempted services; for instance, UnitedHealthcare did specify that they removed requirements for certain nuclear imaging and obstetrical ultrasounds as of January 1. Without those specific procedural codes being published, a “pledge” is often just a change in rhetoric rather than a change in the daily reality of medical billing.
For patients with chronic conditions requiring lifelong medication or transplant support, authorizations often expire annually despite unchanged medical needs. What are the clinical risks of these recurring reviews, and how can providers more effectively argue for permanent approvals to avoid dangerous gaps in life-sustaining treatment?
The clinical risks are immense, as even a 48-hour gap in treatment for a transplant recipient can trigger an irreversible rejection episode. We see cases like the 25-year-old heart transplant patient in Ohio who has been on the same anti-rejection medication for over 10 years, yet her insurer suddenly began a cycle of repeated denials. These annual expirations force patients into a “fight to survive” every 12 months, creating a hazardous environment where life-sustaining care is treated as a temporary trial. Providers must document the “treatment history” aggressively, as insurers sometimes admit—as in this case—that they failed to account for a decade of successful therapy when issuing a denial. To fight for permanent status, clinicians should emphasize the catastrophic cost of a “rebound” illness compared to the steady cost of maintenance, essentially framing the request as a long-term risk management strategy.
When insurers deny expensive treatments like blood plasma infusions, families often resort to spending retirement savings or launching fundraisers to cover five-figure bills. Beyond the immediate financial strain, how does this economic pressure impact long-term health outcomes and the psychological well-being of a patient fighting for care?
The economic pressure creates a “toxic stress” that can physically exacerbate the very conditions the patient is trying to treat. Imagine the psychological toll on a 31-year-old with small-fiber neuropathy, whose limbs feel like they are on fire, watching her parents withdraw $90,000 from retirement savings just to keep her functional. Families are often forced into crowdfunding, like the $30,000 GoFundMe campaign for a patient with a rare genetic lung condition, which adds a layer of public vulnerability to an already private medical crisis. This financial depletion means that even if a denial is eventually overturned, the family’s long-term security is shattered, leaving them with no safety net for future healthcare needs. The feeling of having to “convince someone you deserve to survive” creates a sense of betrayal that can lead to medical PTSD and a profound distrust of the healthcare system.
External reviews by state agencies sometimes overturn insurer denials by citing evidence-based standards that the company initially rejected. Could you walk through the step-by-step process of preparing a successful appeal for an external board, and what types of clinical documentation typically carry the most weight?
A successful external appeal, such as the one that finally forced Anthem to cover $10,000 IVIG infusions in Virginia, requires a shift from emotional pleading to rigorous, evidence-based argumentation. First, you must exhaust the internal appeals process, and then move to a state bureau of insurance which assigns an independent reviewer who isn’t on the insurer’s payroll. The documentation that carries the most weight includes peer-reviewed studies showing the efficacy of the drug for that specific diagnosis and, crucially, a detailed “failure of alternatives” log. If you can prove that the insurer’s preferred, cheaper treatments failed or would be medically contraindicated, the external board is much more likely to rule that the requested care is medically necessary. It is about proving the insurer’s “evidence-based standards” are actually out of step with the broader medical consensus, which is exactly how the Virginia reversal was achieved.
Some insurers are now bundling authorizations for complex procedures like cancer treatments or musculoskeletal surgeries to streamline the process. How does this shift from individual code approvals to “bundled” requests change the daily workflow for medical billing offices, and what potential loopholes might still exist within these systems?
Bundling, as adopted by Aetna CVS Health for lung, breast, and prostate cancer, is a significant administrative relief because it allows a provider to file one request for a whole course of treatment rather than individual codes for every scan and injection. In a traditional workflow, a billing office might spend dozens of hours a week chasing ten different approvals for a single surgery; bundling consolidates that effort. However, the loophole lies in the “scope” of the bundle—if a patient develops a complication or needs a slightly different medication that wasn’t in the original bundled “package,” the office is right back at square one. Furthermore, if the bundle expires before the treatment is completed, the patient faces the same “cliff” of denial that we see in traditional authorizations, meaning the underlying issue of time-limited approvals remains unsolved.
Even after winning a long battle for coverage, patients transitioning to new insurance plans often have to start the entire authorization process over from scratch. What strategies can families use to ensure continuity of care during a plan transition, and how can they best prepare for potential denials?
Continuity of care is one of the most fragile points in the American system, especially for those transitioning from COBRA or changing employers. Families should request a “Transition of Care” (TOC) period from the new insurer immediately, which can sometimes provide a 30 to 90-day window of automatic coverage for ongoing treatments. It is vital to obtain the full medical record and the previous insurer’s approval letter to present to the new company as “proof of clinical stability.” Despite these steps, many patients find themselves starting over, which is why preparing a “denial kit” with your doctor—including the previous external review decisions—is essential. You have to be ready to fight the same battle from day one, as the new insurer has no legal obligation to honor the previous company’s clinical decisions.
What is your forecast for prior authorization reform?
I anticipate that the era of voluntary industry pledges is nearing its end because, as we have seen, the fiduciary responsibility of these companies is often to Wall Street rather than the patient. While some insurers like Humana have removed requirements for basic diagnostic services like colonoscopies, the 39% of chronic patients who cite prior authorization as their “single biggest burden” suggests the problem is too systemic for self-regulation. My forecast is that we will see a move toward mandatory federal “gold-carding” legislation, which would exempt physicians with high approval rates from these requirements entirely. Until that becomes law, patients will continue to face a “living hell” of administrative hurdles, and the gap between clinical necessity and corporate approval will remain a dangerous chasm for the most vulnerable among us.
